Votrient (GSK) is non inferior to Sutent ( Pfizer) in COMPRAZ study for Renal Cell Carcinoma

GSK announced that the pivotal Phase III study COMPARZ has met its primary endpoint. In the open-label, head-to-head study, Votrient (pazopanib) from GSK demonstrated non-inferiority to Sutent (sunitinib) from Pfizer in terms of progression free survival. Patients in the study were treated for advanced Renal Cell Carcinoma (mRCC) with a component of clear cell histology and had received no prior systemic therapy for advanced or metastatic Renal Cell Carcinoma. The findings were presented by lead investigator, Robert J. Motzer, MD, of the Memorial Sloan-Kettering Cancer Center during the 1 October Presidential Symposium of the ESMO 2012 Congress of the European Society for Medical Oncology held in Vienna, Austria.